RT Journal Article
SR Electronic
T1 Prevalence and Clinical Implications of Heightened Plastic Chemical Exposure in Pediatric Patients Undergoing Cardiopulmonary Bypass
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.02.23289379
DO 10.1101/2023.05.02.23289379
A1 Guerrelli, Devon
A1 Desai, Manan
A1 Semaan, Youssef
A1 Essa, Yasin
A1 Zurakowski, David
A1 Cendali, Francesca I.
A1 Reisz, Julie A
A1 D’Alessandro, Angelo
A1 Luban, Naomi C
A1 Posnack, Nikki Gillum
YR 2023
UL http://medrxiv.org/content/early/2023/05/02/2023.05.02.23289379.abstract
AB Importance Phthalate chemicals are used to manufacture disposable plastic medical products, including blood storage bags and components of cardiopulmonary bypass (CPB) circuits. During cardiac surgery, patients can be inadvertently exposed to phthalate chemicals that are released from these plastic products.Objective To quantify iatrogenic phthalate chemical exposure in pediatric patients undergoing cardiac surgery, and examine the link between phthalate exposure and post-operative outcomes.Design, Setting, and Participants The study cohort included 122 pediatric patients undergoing cardiac surgery at Children’s National Hospital. For each patient, a single plasma sample was collected pre-operatively and two additional samples were collected post-operatively upon return from the operating room (post-operative day 0) and the morning after surgery (post-operative day 1).Exposures Concentrations of di(2-ethylhexyl)phthalate (DEHP) and its metabolites were quantified using ultra high-pressure liquid chromatography coupled to mass spectrometry.Main Outcomes and Measures Plasma concentrations of phthalates, post-operative blood gas measurements, and post-operative complications.Results Study subjects were subdivided into three groups, according to surgical procedure: 1) cardiac surgery not requiring CPB support, 2) cardiac surgery requiring CPB with crystalloid prime, and 3) cardiac surgery requiring CPB with red blood cells (RBCs) to prime the circuit. Phthalate metabolites were detected in all patients, and postoperative phthalate levels were highest in patients undergoing CPB with RBC-based prime. Age-matched (<1 year) CPB patients with elevated phthalate exposure were more likely to experience post-operative complications, including arrhythmias, low cardiac output syndrome, and additional post-operative interventions. RBC washing was an effective strategy to reduce DEHP levels in CPB prime.Conclusions and Relevance Pediatric cardiac surgery patients are exposed to phthalate chemicals from plastic medical products, and the degree of exposure increases in the context of CPB with RBC-based prime. Additional studies are warranted to measure the direct effect of phthalates on patient health outcomes and investigate mitigation strategies to reduce exposure.Question Is cardiac surgery with cardiopulmonary bypass a significant source of phthalate chemical exposure in pediatric patients?Findings In this study of 122 pediatric cardiac surgery patients, phthalate metabolites were quantified from blood samples before and after surgery. Phthalate concentrations were highest in patients undergoing cardiopulmonary bypass with red blood cell-based prime. Heightened phthalate exposure was associated with post-operative complications.Meaning Cardiopulmonary bypass is a significant source of phthalate chemical exposure, and patients with heightened exposure may be at greater risk for postoperative cardiovascular complications.Graphical Abstract Pediatric cardiac surgery patients undergoing cardiopulmonary bypass are exposed to phthalate plasticizers through contact with plastic medical devices manufactured with DEHP (indicated with blue outline), including blood product and crystalloid solution storage bags, tubing, cannulas, and reservoirs. The leached DEHP chemical (indicated with blue circles) can localize to the heart, where it can contribute to post-operative complications. DEHP: Di(2-ethylhexyl)phthalate, ET: endotracheal tube, FFP: fresh frozen plasma, RBCs: red blood cells.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNGP was supported by the National Heart, Lung, and Blood Institute (R01HL139472), Childrens Research Institute, and Childrens National Heart Institute. DG was supported by the American Heart Association (23PRE1021149). AD was supported by the National Institute of General and Medical Sciences (RM1GM131968), and from the National Heart, Lung, and Blood Institute (R01HL146442, R01HL149714, R01HL148151, R01HL161004).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Childrens National Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe participants of this study did not give written consent for their data to be shared publicly; data to support the findings of this study are available on request from the corresponding author.CPBCardiopulmonary bypassDEHPDi(2-ethyhexyl)phthalateFDRFalse discovery rateFFPFresh frozen plasmaMECPPMono(2-ethyl-5-carboxypentyl)phthalateMEHHPMono(2-ethyl-5-hydroxyhexyl)phthalateMEHPMono(2-ethylhexyl)phthalateNICUNeonatal Intensive Care UnitPICUPediatric Intensive Care UnitPOD0Post-operative day 0POD1Post-operative day 1Pre-opPre-operativeRBCsRed blood cells